Background Currently a couple of no biomarkers that can predict the incidence of dengue shock and/or organ failure although the early recognition of risk factors is important in determining appropriate management to reduce mortality. study was carried out among adults hospitalized for confirmed viral dengue illness at the Hospital for Tropical Diseases in Bangkok Thailand between October 2013 and July 2015. Data including baseline characteristics clinical parameters laboratory findings serum PCT and PVL levels management and results were recorded on pre-defined case statement forms. Of 160 individuals with dengue 128 Sorafenib (80.0%) individuals had dengue without shock or organ failure whereas 32 (20.0%) individuals developed dengue with shock and/or organ failure. Using a stepwise multivariate logistic regression analysis PCT ≥0.7 ng/mL (odds Sorafenib ratio [OR]: 4.80; 95% confidence interval [CI]: 1.60-14.45; = 0.005) and PVL ≥2.5 mmol/L (OR: 27.99 95 CI: 8.47-92.53; <0.001) were independently associated with dengue shock and/or organ failure. A combination of PCT ≥0.7 ng/mL and PVL ≥2.5 mmol/L provided good prognostic value for predicting dengue shock and/or organ failure with an area under the receiver operating characteristics curve of 0.83 (95% CI: 0.74-0.92) a sensitivity of 81.2% (95% CI: 63.6-92.8%) and a specificity of 84.4% (95% CI: 76.9-90.2%). Dengue shock patients with non-clearance of PCT and PVL expired during hospitalization. Conclusions/Significance PCT ≥0.7 ng/mL and PVL ≥2.5 mmol/L were independently associated with dengue shock and/or organ failure. The combination of PCT and PVL levels could be used as prognostic biomarkers for the prediction of dengue shock and/or organ failure. Author Summary Dengue is a major global health concern particularly in tropical countries and affects all age groups. Mortality rates among patients who have been hospitalized with severe dengue are 1.6-10.9% and death in adults is mainly due to the development of dengue shock and organ dysfunction. In states of poor tissue circulation or shock lactate is produced. Additionally procalcitonin is a Sorafenib highly specific biomarker of systemic inflammation. Therefore we assessed whether procalcitonin and peripheral venous lactate could be utilized to forecast the occurrence of dengue surprise Id1 and/or organ failing in individuals with dengue. Our research showed a mix of serum procalcitonin amounts ≥0.7 peripheral and ng/mL venous lactate amounts ≥2.5 mmol/L at admission could discriminate between patients who do and didn’t develop shock and/or organ failure with high sensitivity and specificity. These guidelines could be useful as prognostic biomarkers therefore. Our results claim that serum procalcitonin can be indicative of a thorough early inflammatory response which might occur through the systemic stage of dengue. Peripheral venous lactate could be produced as a complete result of the indegent tissue circulation that precedes dengue shock. Our results can help clinicians to forecast dengue surprise and/or body organ failing previously to lessen in-hospital mortality. Introduction Dengue is the Sorafenib most important arthropod-borne viral disease and it exerts a high burden on populations and public health systems in most tropical countries [1 2 The incidence has dramatically Sorafenib increased during the last 50 years (by 30-fold) for all four dengue virus serotypes (DENV 1-4) in more than 100 countries including those in Southeast Asia Central and South America the Western Pacific Africa and the Eastern Mediterranean [2 3 A previous report estimated that 390 million people are infected with DENV Sorafenib per year worldwide of which 96 million show clinical manifestations of dengue [4]. Clinical manifestations range from acute febrile illness to severe dengue which is a life-threatening condition [1]. In-hospital mortality is observed among 1.6-10.9% of patients with severe manifestations of dengue including dengue hemorrhagic fever and/or dengue shock syndrome [5-7]. The World Health Organization (WHO) has implemented a goal of reducing dengue mortality by at least 20% and morbidity by 25% by the year 2020 [2]. Early recognition of severe dengue would help clinicians achieve close monitoring and provide proper fluid resuscitation in order to prevent severe disease which would reduce mortality.